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Abstract
Aims/hypothesis Cardiovascular disease contributes to mor-
tality in type 1 diabetes mellitus, but the specific patho-
physiological mechanisms remain to be established. We
recently showed that the endothelial glycocalyx, a protec-
tive layer of proteoglycans covering the endothelium, is
severely perturbed in type 1 diabetes, with concomitantly
increased plasma levels of hyaluronan and hyaluronidase.
In the present study, we evaluated the relationship between
hyaluronan and hyaluronidase with carotid intima-media
thickness (cIMT), an established surrogate marker for
cardiovascular disease.
Subjects and methods Non-smoking type 1 diabetes patients
without micro- or macrovascular complications and matched
controls were recruited and cIMTof both carotid arteries was
measured. To evaluate the relationship between cIMT and
hyaluronan and hyaluronidase as well as other parameters,
uni- or multivariate regression analyses were performed.
Results We included 99 type 1 diabetes patients (age 10–
72 years) and 99 age- and sex-matched controls. Mean
cIMT, HbA1c, high sensitivity C-reactive protein, hyaluronan
and hyaluronidase were significantly increased in type 1
diabetes vs controls. Plasma hyaluronan and hyaluronidase
were correlated in type 1 diabetes. In univariate regression
analyses, mean IMT was associated with plasma hyaluronan,
age and male sex, whereas after multivariate analysis only
age and sex remained statistically significant.
Conclusions/interpretation We conclude that type 1 diabe-
tes patients show structural changes of the arterial wall
associated with increased hyaluronan metabolism. These
data may lend further support to altered glycosaminoglycan
metabolism in type 1 diabetes as a potential mechanism
involved in accelerated atherogenesis.
Keywords Hyaluronan.Hyaluronidase.Intima-media
thickness.Type1diabetesmellitus
Abbreviations
ALAT alanine aminotransferase
ASAT aspartate aminotransferase
cIMT carotid intima-media thickness
hsCRP high sensitivity C-reactive protein
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Macro- and microvascular complications are a major cause
o fm o r b i d i t ya n dm o r t a l i t yi np a t i e n t sw i t hd i a b e t e s
mellitus. While the macrovascular complications in patients
with type 2 diabetes mellitus can partly be attributed to the
increased prevalence of classic cardiovascular risk factors
such as dyslipidaemia, these risk factors cannot explain the
increased prevalence of atherosclerosis in type 1 diabetes
mellitus [1–3]. Recent data demonstrated that hyperglycae-
mia itself may play a causative role. Thus, improved
metabolic control is associated with a decreased macro-
vascular event rate [1–3]. However, the pathophysiology of
glucose-associated atherogenesis remains to be elucidated
[4, 5]. In recent years, the glycocalyx has emerged as a
potential orchestrator of vascular homeostasis, which
closely determines anti-adhesive and barrier properties of
the vessel wall [6]. In line, we found that the endothelial
glycocalyx is adversely affected by both acute and chronic
hyperglycaemia in volunteers and type 1 diabetes patients,
respectively [7, 8].
Hyaluronan is a principal constituent of the glycocalyx
and removal of the glycocalyx with hyaluronidase has
been associated with increased vascular vulnerability
towards atherogenic insults [9–11]. In animal models of
type 1 diabetes, hyaluronidase activity has been shown to
be increased and this correlated with increased carotid
intima-media thickness (cIMT) [12–14]. In line with this,
increased accumulation of hyaluronan within the arterial
wall in type 1 diabetes patients correlated with vascular
changes [15]. We recently found an acute increase in
plasma hyaluronan coinciding with glycocalyx perturba-
tion during a normo-insulinaemic–hyperglycaemic clamp
in healthy volunteers [7]. Moreover, we observed an
inverse correlation between plasma hyaluronan as well as
plasma hyaluronidase and glycocalyx volume in patients
with type 1 diabetes [8]. In this concept, hyperglycaemia-
induced perturbation of hyaluronan metabolism, charac-
terised by increased hyaluronidase activity with subsequent
increased plasma hyaluronan levels, may indicate in-
creased vascular vulnerability.
In the present study, we set out to evaluate the potential
relationship between structural changes of the carotid artery
and hyaluronan metabolism in patients with uncomplicated
type 1 diabetes.
Subjects and methods
We enrolled non-smoking Europid patients with type 1
diabetes, all without clinical signs of micro- or macro-
vascular disease. The patients were recruited from the
Internal Medicine outpatient clinics of the Academic
Medical Center and Onze Lieve Vrouwe Gasthuis in
Amsterdam, the Netherlands. The presence of macrovas-
cular disease, defined as ECG abnormalities or a history of
cardiac, cerebral or peripheral vascular events, was an
exclusion criterion for the study. Moreover, subjects with
retinopathy, neuropathy, (micro) albuminuria, or hyperten-
sion were excluded from participation. All patients were on
multiple daily injections of insulin with no other concom-
itant medication use. Matched non-smoking controls (se-
lected for this study specifically) were unrelated volunteers
of similar age and sex. Investigations of both study groups
were randomly performed during the study period. Ap-
proval for the study was obtained from the Internal Review
Board of the Academic Medical Center Amsterdam and all
subjects gave written informed consent. The study was
carried out in accordance with the principles of the
Declaration of Helsinki.
All measurements were performed after an overnight fast
and in a quiet and air-conditioned room. Blood pressure
was measured in triplicate and the last two measurements
were averaged to obtain heart rate and systolic and diastolic
blood pressure. The latter were averaged to calculate mean
blood pressure. At baseline, blood samples were collected
for determination of lipids, high sensitivity C-reactive
protein (hsCRP), HbA1c, hyaluronan and hyaluronidase.
The markers of hepatic function ASAT and ALAT
(aspartate aminotransferase and alanine aminotransferase,
respectively) were determined, since chronic liver disease is
known to be associated with increased plasma hyaluronan
levels [16]. After centrifugation (within 1 h after collec-
tion), aliquots were snap-frozen in liquid nitrogen and
stored at −80°C.
Clinical chemistry Total cholesterol, HDL-cholesterol and
triacylglycerol were measured by enzymatic methods
(Roche Diagnostics, Basel, Switzerland). LDL-cholesterol
was calculated using the Friedewald formula. ALAT and
ASAT were measured by a pyridoxal-phosphate activation
assay (Roche Diagnostics). HbA1c was measured using an
HPLC (Reagens Bio-Rad Laboratories BV, the Nether-
lands) on a Variant II (Bio-Rad Laboratories). Total plasma
hyaluronan and hsCRP levels were determined in dupli-
cates by commercial ELISA (Echelon Biosciences, Salt
Lake City, UT, USA and Roche, Bern, Switzerland,
respectively). Plasma hyaluronidase levels were determined
with a previously described assay [8, 17].
Ultrasound B-mode protocol for cIMT measurement B-
mode ultrasound imaging was used to visualise three
carotid arterial wall segments comprising common carotid,
bulb and internal of the left and right carotid arteries
according to a previously published protocol [18, 19].
Subjects were scanned in the reclined position following a
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10 v (Siemens, Erlangen, Germany) equipped with an L7
linear array transducer and extended frequency software
was used. B-mode images were stored as 4:1 compressed
jpeg files on a digital still recorder (SONY DKR-700 P).
All scans were performed by the same sonographer. To
investigate intra-sonographer reproducibility, ten study
subjects were scanned in duplicate. These investigations
enabled us to provide robust arterial wall thickness
measurements (SD of the means of the paired cIMT
measurements 0.05 mm; CV=9.0%). One image analyst
performed the analyses off-line with semi-automated
quantitative and qualitative video image analysis software.
Both the sonographer and the image analyst were blinded to
the clinical status of the subjects. These images provided
the cIMT data. Mean cIMT was defined as the mean cIMT
of the right and left common carotid, the carotid bulb and
the internal carotid far wall segments. For a given segment,
cIMT was defined as the average of the right and left cIMT
measurements. The per-patient averaged means of the cIMT
values of segments was used for the primary analysis.
Statistical analysis Mean values of continuous variables
between type 1 diabetes patients and controls were
compared using Student’s t test for independent samples.
In the case of a skewed distribution the t test was
performed on log-transformed values, while medians and
interquartile ranges are presented. Chi-square tests were
applied for comparison of distribution of dichotomous
data. Correlation between hyaluronan and hyaluronidase
was calculated by Spearman’s rank coefficient (two-
tailed). In this study our main interest was to find
predictors for type 1 diabetes-associated atherosclerosis
and vascular dysfunction. The relationship between the
dependent variable cIMT on the one hand and other
parameters (e.g. plasma hyaluronan) on the other was
first explored univariably using linear regression analysis.
For clinical variables and variables which revealed
statistically significant correlations in the univariate
analysis, estimates of cIMT adjusted for confounding
were calculated with SPSS version 11.5 (Chicago, IL,
USA). In addition, several multivariate models were built
to explore the effects of age, sex and the statistically
significant variables on cIMT. Throughout, a two tailed p
value <0.05 was considered statistically significant.
Results
Clinical characteristics of the 99 type 1 diabetes subjects
and 99 matched controls are listed in Table 1. There was no
significant difference between type 1 diabetes subjects and
controls with regard to age, sex, BMI, systolic and diastolic
blood pressure, liver function tests and cholesterol profile.
However, we did observe increased values for HbA1c,
heart rate, plasma hsCRP, hyaluronan and hyaluronidase in
type 1 diabetes patients. A significant correlation was
found between plasma hyaluronan and hyaluronidase
activity in type 1 diabetes (r=0.3, p<0.05, see Fig. 1a).
After exclusion of the highest hyaluronidase activity levels
(levels >750 U/ml), the correlation between hyaluronan
and hyaluronidase levels was still present. Liver function
tests (ASAT and ALAT) were not significantly associated
with plasma hyaluronan levels in type 1 diabetes.
Mean cIMT was increased in the type 1 diabetes
group compared with controls (0.61±0.15 vs 0.53±
0.12 mm, p<0.001). In type 1 diabetes subjects plasma
hyaluronan levels (Fig. 1b ) ,a g e ,m a l es e x ,d u r a t i o no f
diabetes and mean blood pressure were positively corre-
lated with mean cIMT in univariate analysis. No dose-
dependent relationship between insulin dose, HbA1c levels
and mean cIMT was found in these patients. However,
upon multivariate linear regression analysis only age and
sex remained significantly associated with cIMT (Table 2).
Table 1 Demographic and baseline parameters of the study cohort
Type 1 diabetes
patients
Controls
Number of participants 99 99
Sex (male/female) 44/55 44/55
Age (years) 32.8±14.8 34.9±16.4
Duration of diabetes (years) 16.4±11.9 –
Daily insulin dose (IU) 52.9±20.3 –
Smoking (yes/no) 0/99 0/99
BMI (kg/m
2) 23.4±3.5 23.3±3.6
Systolic blood pressure
(mmHg)
123±17 125±20
Diastolic blood pressure
(mmHg)
72±9 73±12
Heart rate (beats/min) 71±11** 60±14
Total cholesterol (mmol/l) 4.9±0.9 4.9±1.0
LDL-cholesterol (mmol/l) 2.8±0.7 2.9±0.8
HDL-cholesterol (mmol/l) 1.6±0.5 1.5±0.4
Triacylglycerol (mmol/l) 0.9 (0.5–1.1) 1.0 (0.5–
1.2)
ASAT (U/l) 24 (21–27) 25 (21–29)
ALAT (U/l) 22 (15–28) 20 (14–24)
HbA1c (%) 8.3±1.6** 5.1±0.3
Hyaluronan (ng/ml) 78±43* 60±18
Hyaluronidase (U/ml) 362±23** 242±13
hsCRP (mg/l) 2.6 (0.4–2.9)* 1.1 (0.2–
2.0)
cIMT (mm) 0.61±0.15** 0.53±0.12
Data are means±SD, except for triacylglycerol, ASAT, ALAT and
hsCRP, which are expressed as median (inter-quartile range).
*p<0.05, **p<0.01 type 1 diabetes patients vs controls
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In line with expectation, type 1 diabetes patients were
characterised by structural changes of the arterial wall. In
addition, we observed significant elevations of plasma
hyaluronan and hyaluronidase activity levels in type 1
diabetes patients, whereas hyaluronan was correlated to
cIMT. These present data imply that disturbances of
hyaluronan metabolism may be associated with vascular
damage in type 1 diabetes patients.
Intima-media thickness in type 1 diabetes We observed a
significant increase in cIMT in type 1 diabetes patients
without micro- or macro-vascular complications compared
with controls and confirmed that male sex is associated
with an increased cIMT [3]. Despite the cross-sectional
design of our study, this finding is compatible with data
from the longitudinal DCCT study [3]. LDL-cholesterol
was not associated with cIMT progression in the DCCT
cohort, underscoring a potential role for hyperglycaemia in
diabetic atherogenesis [1, 20, 21]. In contrast to the DCCT
findings, we did not find a correlation between cIMT and
glycaemic status. This apparent discrepancy may have
several explanations. First, a single determination of HbA1c
in our study may not be a reliable reflection of glycaemic
excursions over the last months to years. In the DCCT,
HbA1c was evaluated repetitively in a prospective cohort of
type 1 diabetes patients, all receiving an intensive treatment
regimen [1, 3]. Under these circumstances, HbA1c was
predictive of cIMT progression over the next 4 years.
Second, the elderly patients in our cohort may have been
exposed to longer periods of poorly controlled diabetes
followed by more intensive treatment regimens only in the
last few years. As a consequence, their present HbA1c
levels may have underestimated long-term glycaemic
exposure.
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Fig. 1 a Relationship between plasma hyaluronan levels and plasma
hyaluronidase activity in type 1 diabetes patients. b Relationship
between plasma hyaluronan levels and cIMT in type 1 diabetes
patients
Table 2 Univariate and multivariate associations of cIMT with
various risk factors in patients with type 1 diabetes
Parameter Univariate β
coefficient
p
value
Multivariate β
coefficient
p
value
Female sex −0.86* 0.005 −0.048* 0.029
Age 0.007* 0.001 0.07* 0.0001
Duration of
diabetes
0.008* 0.001 −0.110 0.340
Daily insulin
dose
−0.001 0.109
BMI 0.004 0.433
Mean blood
pressure
0.004* 0.004 −0.027 0.726
Heart rate 0.0001 0.994
Total
cholesterol
0.016 0.366
LDL-
cholesterol
0.021 0.321
HDL-
cholesterol
0.026 0.416
Triacylglycerol −0.054 0.076
ASAT 0.037 0.615
ALAT −0.019 0.589
HbA1c −0.008 0.441
Hyaluronan 0.126* 0.001 0.116 0.130
Hyaluronidase 0.036 0.731
hsCRP −0.013 0.306
*p<0.05 type 1 diabetes patients vs controls
Diabetologia (2007) 50:1288–1293 1291Hyaluronan metabolism and type 1 diabetes Hyaluronan is
the principal constituent of endothelial glycocalyx as well
as the extra-cellular matrix [7–10, 14, 15, 22]. Since the
glycocalyx is a principal determinant of vascular perme-
ability for macromolecules (e.g. lipoproteins), glycocalyx
loss may contribute to the increased transvascular leakage
of lipoproteins in patients with type 1 diabetes [20]. Indeed
exposure of the carotid artery to atherogenic challenges in
mice resulted in increased plasma hyaluronan shedding,
concomitant loss of endothelial glycocalyx and increased
cIMT [23, 24]. In line, we observed that patients with
uncomplicated type 1 diabetes have a profound reduction of
endothelial glycocalyx, which was associated with in-
creased plasma hyaluronan and hyaluronidase levels [8].
In fact, in the present study we find a positive correlation
between plasma hyaluronan and cIMT thickness. Upon
multivariate analysis this correlation was lost, most likely
due to the fact that age and sex are very closely associated
with cIMT, thus attenuating the predictive value of
hyaluronan [19]. We did not find a relationship between
chronic inflammation as measured by hsCRP and plasma
hyaluronan in type 1 diabetes. Therefore further studies are
needed to evaluate the effect of other inflammatory markers
(e.g. leucocyte count) on hyaluronan metabolism in these
patients.
Collectively, the present finding implies that hyper-
glycaemia may elicit alterations in hyaluronan metabolism,
which are likely to reflect glycocalyx perturbation. The
latter facilitates a wide array of pro-atherogenic effects,
including vascular dysfunction and increased permeability
of the vessel wall for, for example, lipoproteins. In line,
aggregation of calcium with hyaluronan (and other sub-
endothelial glycosaminoglycans) could enhance ectopic
calcification of the cIMT, which is increased in type 1
diabetes patients [25, 26]. It would be interesting to
investigate whether therapeutic intervention aimed at this
disturbed hyaluronan metabolism in type 1 diabetes has the
potential to reverse the pro-atherogenic state in these
patients [27, 28].
Study limitations Several methodological aspects of our
study merit caution. We did not determine fasting plasma
glucose levels in our type 1 diabetes subjects, therefore we
were only able to study markers of chronic hyperglycaemia
(HbA1c) on vascular dysfunction. Moreover, the observa-
tional nature of our study combined with the use of
surrogate markers of future vascular disease can be
considered a weakness. However, solid evidence exists that
changes in arterial wall function are predictive of cardio-
vascular outcome [29, 30]. In addition, reproducibility of
the measurements was excellent, since a single ultrasound
machine was used, one experienced sonographer performed
all ultrasonography and images were analysed by a single
reader. To reduce variability further, image analysis
software automatically investigated each measurement.
Finally endothelial glycocalyx also comprises other
glycosaminoglycans such as syndecan, chondroitin sulphate
and heparan sulphate, which all have their own function [6,
31]. Since hyaluronan and heparan sulphate are important
in shear stress-mediated nitric oxide production, which is
inextricably entangled with atherosclerosis, further research
is needed to explore the role of these other endothelial
glycocalyx compounds on diabetes mellitus associated
vascular dysfunction.
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